On June 10, 2026 ExCellThera Inc. ("ExCellThera"), a global leader in blood stem cell expansion and metabolic fitness technologies, together with its wholly owned subsidiary Cordex Biologics ("Cordex"), reported exclusive licensing and supply agreements granting Medexus the Canadian commercialization rights for Zemcelpro (dorocubicel), also known as UM171 Cell Therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Zemcelpro is a novel personalized cryopreserved hematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. The product is used to treat hematological malignancies (blood cancers), such as leukemias and myelodysplasias. Given the product’s current stage of development in Canada, Medexus does not expect to begin commercializing the product before calendar year 2028 (depending on available regulatory pathways). As part of the regulatory process, Medexus intends to seek Health Canada approval of the brand name Zemcelpro.
"These agreements with Medexus represent today an important milestone and reflect our continued commitment to advancing Zemcelpro for patients with significant unmet medical needs," said David Millette, CEO of Cordex. "In addition to the strong commercial opportunity this partnership creates, we believe it has the potential to meaningfully improve access to innovative therapies for Canadian patients with high-risk blood cancers requiring allogeneic stem cell transplantation, where new treatment options remain critically needed."
Medexus is a leading specialty pharmaceutical company with extensive experience in hematology and oncology, making it a strong strategic fit for the partnership with Cordex.
Importantly, this agreement also represents a broader step forward in Cordex’s global commercialization strategy for Zemcelpro. Cordex continues to actively pursue additional strategic partnerships to support and accelerate the commercialization of Zemcelpro across Europe and other international markets.
"We believe there is substantial global interest in innovative therapies that address persistent unmet needs in blood malignancies and conventional stem cell transplantation, and we remain focused on identifying partners with the expertise, infrastructure, and shared vision necessary to expand patient access worldwide," said David Millette. "As we advance these discussions, our priority remains clear: bringing innovative and potentially life-changing therapies to patients who urgently need new treatment options while creating long-term value for our stakeholders."
The transaction includes royalties on Canadian net sales and milestone payments, creating a shared economic interest in the product’s long-term commercial success. Cordex will continue to manage the clinical program and will be responsible for the manufacturing and supply of Zemcelpro to Medexus.
About Zemcelpro
Zemcelpro (dorocubicel), also known as UM171 Cell Therapy, is a novel personalized cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit.
Zemcelpro has recently received conditional marketing authorization from the European Commission for the treatment of adults with haematological malignancies requiring allogeneic haematopoietic stem cell transplantation following myeloablative conditioning, for whom no other suitable donor cells are available. For complete product information, including warnings and precautions for use and adverse reactions (and their appropriate management), please refer to the EU Summary of Product Characteristics (SmPC) for Zemcelpro.
Additional regulatory filings are planned for Zemcelpro with other health authorities, including in the US, Canada, the UK, and Switzerland.
Zemcelpro has been evaluated in over 120 patients with haematologic malignancies in clinical trials in the United States, Europe and Canada. Zemcelpro has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designations from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA.
Zemcelpro has been tested in Phase 2 trials in patients with high- and very high-risk acute leukemias and myelodysplasias who have limited treatment options with low survival outcomes and high incidence of relapse under the current standard of care, including patients with patients with TP53 mutations or other genetic abnormalities, patients requiring a second transplant, and patients with refractory or active disease. A pivotal Phase 3 trial in this patient population will be initiated as soon as possible.
The use of Zemcelpro in other patient populations, including pediatric patients and patients with non-malignant haematological diseases, is also being investigated.
The product safety and efficacy have not yet been established by other regulatory agencies, such as the U.S. FDA, the MHRA and Health Canada.
(Press release, ExCellThera, JUN 10, 2026, View Source [SID1234666542])